Literature DB >> 22661321

Ubiquilin immunoreactivity in cytoplasmic and nuclear inclusions in synucleinopathies, polyglutamine diseases and intranuclear inclusion body disease.

Fumiaki Mori1, Kunikazu Tanji, Saori Odagiri, Yasuko Toyoshima, Mari Yoshida, Teruaki Ikeda, Hidenao Sasaki, Akiyoshi Kakita, Hitoshi Takahashi, Koichi Wakabayashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22661321     DOI： 10.1007/s00401-012-0999-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  19 in total

1.  Dominant-negative function of the C-terminal fragments of NBR1 and SQSTM1 generated during enteroviral infection.

Authors:  J Shi; G Fung; P Piesik; J Zhang; H Luo
Journal:  Cell Death Differ       Date:  2014-04-25       Impact factor: 15.828

Review 2.  Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects.

Authors:  Glenda Halliday; Eileen H Bigio; Nigel J Cairns; Manuela Neumann; Ian R A Mackenzie; David M A Mann
Journal:  Acta Neuropathol       Date:  2012-08-10       Impact factor: 17.088

3.  Ubiquilin-2 differentially regulates polyglutamine disease proteins.

Authors:  Julia E Gerson; Nathaniel Safren; Svetlana Fischer; Ronak Patel; Emily V Crowley; Jacqueline P Welday; Alexandra K Windle; Sami Barmada; Henry L Paulson; Lisa M Sharkey
Journal:  Hum Mol Genet       Date:  2020-08-29       Impact factor: 6.150

4.  Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3.

Authors:  Li Zeng; Bo Wang; Sean A Merillat; Eiko N Minakawa; Matthew D Perkins; Biswarathan Ramani; Sara J Tallaksen-Greene; Maria do Carmo Costa; Roger L Albin; Henry L Paulson
Journal:  Neurobiol Dis       Date:  2015-06-30       Impact factor: 5.996

5.  Signature changes in ubiquilin expression in the R6/2 mouse model of Huntington's disease.

Authors:  Nathaniel Safren; Lydia Chang; Kristina M Dziki; Mervyn J Monteiro
Journal:  Brain Res       Date:  2014-12-12       Impact factor: 3.252

6.  RTL8 promotes nuclear localization of UBQLN2 to subnuclear compartments associated with protein quality control.

Authors:  Harihar Milaganur Mohan; Hanna Trzeciakiewicz; Amit Pithadia; Emily V Crowley; Regina Pacitto; Nathaniel Safren; Bryce Trotter; Chengxin Zhang; Xiaogen Zhou; Yang Zhang; Venkatesha Basrur; Henry L Paulson; Lisa M Sharkey
Journal:  Cell Mol Life Sci       Date:  2022-03-05       Impact factor: 9.207

7.  Disrupting the Balance of Protein Quality Control Protein UBQLN2 Accelerates Tau Proteinopathy.

Authors:  Julia E Gerson; Stephanie Sandoval-Pistorius; Jacqueline P Welday; Aleija Rodriguez; Jordan D Gregory; Nyjerus Liggans; Kylie Schache; Xingli Li; Hanna Trzeciakiewicz; Sami Barmada; Lisa M Sharkey; Henry L Paulson
Journal:  J Neurosci       Date:  2022-01-26       Impact factor: 6.709

8.  Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions.

Authors:  Nicola J Rutherford; Jada Lewis; Amy K Clippinger; Michael A Thomas; Jennifer Adamson; Pedro E Cruz; Ashley Cannon; Guilian Xu; Todd E Golde; Gerry Shaw; David R Borchelt; Benoit I Giasson
Journal:  Brain Res       Date:  2013-06-15       Impact factor: 3.252

9.  Mutant UBQLN2 promotes toxicity by modulating intrinsic self-assembly.

Authors:  Lisa M Sharkey; Nathaniel Safren; Amit S Pithadia; Julia E Gerson; Mark Dulchavsky; Svetlana Fischer; Ronak Patel; Gabrielle Lantis; Naila Ashraf; John H Kim; Alia Meliki; Eiko N Minakawa; Sami J Barmada; Magdalena I Ivanova; Henry L Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-17       Impact factor: 11.205

10.  Ubiquitin Modulates Liquid-Liquid Phase Separation of UBQLN2 via Disruption of Multivalent Interactions.

Authors:  Thuy P Dao; Regina-Maria Kolaitis; Hong Joo Kim; Kevin O'Donovan; Brian Martyniak; Erica Colicino; Heidi Hehnly; J Paul Taylor; Carlos A Castañeda
Journal:  Mol Cell       Date:  2018-03-08       Impact factor: 17.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.